Capricor Therapeutics (CAPR) Stock Forecast, Price Target & Predictions
CAPR Stock Forecast
Capricor Therapeutics stock forecast is as follows: an average price target of $14.00 (represents a 205.01% upside from CAPR’s last price of $4.59) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
CAPR Price Target
The average price target for Capricor Therapeutics (CAPR) is $14.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $14.00 to $14.00. This represents a potential 205.01% upside from CAPR's last price of $4.59.
CAPR Analyst Ratings
According to 3 Wall Street analysts, Capricor Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CAPR stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Capricor Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| May 16, 2024 | Leland Gershall | Oppenheimer | $14.00 | $5.64 | 148.23% | 205.01% |
The latest Capricor Therapeutics stock forecast, released on May 16, 2024 by Leland Gershall from Oppenheimer, set a price target of $14.00, which represents a 148.23% increase from the stock price at the time of the forecast ($5.64), and a 205.01% increase from CAPR last price ($4.59).
Capricor Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $14.00 |
| Last Closing Price | $4.59 | $4.59 | $4.59 |
| Upside/Downside | -100.00% | -100.00% | 205.01% |
In the current month, the average price target of Capricor Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Capricor Therapeutics's last price of $4.59. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 02, 2024 | Oppenheimer | Buy | Buy | Hold |
| Jul 02, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 16, 2024 | Oppenheimer | - | Outperform | Initialise |
| May 14, 2024 | Ladenburg Thalmann & Co. | Buy | Buy | Hold |
Capricor Therapeutics's last stock rating was published by Oppenheimer on Jul 02, 2024. The company gave CAPR a "Buy" rating, the same as its previous rate.
Capricor Therapeutics Financial Forecast
Capricor Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $12.09M | $6.19M | $3.92M | $2.99M | $957.35K | $1.59M | - | - | $204.08K | $57.83K | $16.86K | $49.86K | $185.69K | $222.10K | $142.07K | $410.35K | $230.50K | $219.25K | $403.96K | $400.07K | $313.27K | $996.46K |
| Avg Forecast | $5.00M | $5.00M | $4.00M | $3.50M | $7.85M | $4.48M | $4.58M | $9.70M | $10.60M | $3.15M | $3.00M | $1.00M | $10.00K | $420.00K | $390.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $210.00K | $70.00K | $220.00K | $220.00K | $430.00K | $227.08K | $357.14K | $342.86K | $490.83K | $1.13M |
| High Forecast | $5.00M | $5.00M | $4.00M | $3.50M | $7.85M | $5.19M | $4.58M | $9.70M | $10.60M | $3.15M | $3.00M | $1.00M | $10.00K | $420.00K | $390.00K | $268.12K | $268.12K | $268.12K | $268.12K | $268.12K | $268.12K | $89.37K | $280.89K | $280.89K | $549.01K | $272.50K | $428.57K | $411.43K | $589.00K | $1.35M |
| Low Forecast | $5.00M | $5.00M | $4.00M | $3.50M | $7.85M | $3.75M | $4.58M | $9.70M | $10.60M | $3.15M | $3.00M | $1.00M | $10.00K | $420.00K | $390.00K | $149.55K | $149.55K | $149.55K | $149.55K | $149.55K | $149.55K | $49.85K | $156.67K | $156.67K | $306.22K | $181.66K | $285.71K | $274.28K | $392.67K | $900.00K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 1 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 11 | 19 | 20 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | 1.14% | 1.96% | 1.31% | 2.99% | 95.74% | 3.79% | - | - | 0.97% | 0.28% | 0.08% | 0.24% | 0.88% | 3.17% | 0.65% | 1.87% | 0.54% | 0.97% | 1.13% | 1.17% | 0.64% | 0.89% |
Capricor Therapeutics's average Quarter revenue forecast for Mar 24 based on 1 analysts is $9.70M, with a low forecast of $9.70M, and a high forecast of $9.70M. CAPR's average Quarter revenue forecast represents a -19.76% decrease compared to the company's last Quarter revenue of $12.09M (Dec 23).
Capricor Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 1 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 11 | 19 | 20 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | $-1.06M | $-6.86M | $-8.13M | $-8.60M | $-8.41M | $-6.45M | - | $-3.87M | $-4.70M | $-4.14M | $-3.87M | $-3.45M | $-2.05M | $-1.43M | $-1.56M | $-2.00M | $-2.48M | $-4.09M | $-4.08M | $-3.64M | $-2.59M | $-3.33M |
| Avg Forecast | $-4.91M | $-4.91M | $-3.93M | $-3.44M | $-7.72M | $-4.40M | $-4.50M | $-9.53M | $-10.42M | $-3.10M | $-2.95M | $-982.77K | $-9.83K | $-412.76K | $-383.28K | $-5.23M | $-5.10M | $-206.38K | $-206.38K | $-4.76M | $-2.24M | $-68.79K | $-2.17M | $-2.53M | $-422.59K | $-4.24M | $-3.59M | $-3.03M | $-3.55M | $-3.70M |
| High Forecast | $-4.91M | $-4.91M | $-3.93M | $-3.44M | $-7.72M | $-3.69M | $-4.50M | $-9.53M | $-10.42M | $-3.10M | $-2.95M | $-982.77K | $-9.83K | $-412.76K | $-383.28K | $-4.19M | $-4.08M | $-146.97K | $-146.97K | $-3.81M | $-1.79M | $-48.99K | $-1.73M | $-2.02M | $-300.94K | $-3.39M | $-2.88M | $-2.42M | $-2.84M | $-2.96M |
| Low Forecast | $-4.91M | $-4.91M | $-3.93M | $-3.44M | $-7.72M | $-5.10M | $-4.50M | $-9.53M | $-10.42M | $-3.10M | $-2.95M | $-982.77K | $-9.83K | $-412.76K | $-383.28K | $-6.28M | $-6.13M | $-263.50K | $-263.50K | $-5.71M | $-2.69M | $-87.83K | $-2.60M | $-3.04M | $-539.55K | $-5.08M | $-4.31M | $-3.64M | $-4.26M | $-4.44M |
| Surprise % | - | - | - | - | - | - | - | - | 0.10% | 2.22% | 2.76% | 8.75% | 855.99% | 15.62% | - | 0.74% | 0.92% | 20.04% | 18.77% | 0.73% | 0.92% | 20.74% | 0.72% | 0.79% | 5.86% | 0.97% | 1.14% | 1.20% | 0.73% | 0.90% |
undefined analysts predict CAPR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Capricor Therapeutics's previous annual EBITDA (undefined) of $NaN.
Capricor Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 1 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 11 | 19 | 20 | 18 |
| Net Income | - | - | - | - | - | - | - | - | $-762.09K | $-6.39M | $-7.37M | $408.67M | $-7.83M | $-6.26M | - | $-3.93M | $-4.75M | $-4.18M | $-3.91M | $-3.48M | $-2.08M | $-1.47M | $-1.61M | $-2.05M | $-2.52M | $-4.14M | $-4.12M | $-3.67M | $-2.73M | $-3.47M |
| Avg Forecast | $-10.19M | $-9.23M | $-9.07M | $-8.92M | $-9.15M | $-11.70M | $-11.34M | $-3.62M | $-2.87M | $-9.66M | $-11.14M | $-10.19M | $-10.83M | $-10.19M | $-8.00M | $-4.83M | $-5.16M | $-6.13M | $-5.52M | $-4.80M | $-2.27M | $-10.43M | $-2.23M | $-2.58M | $-33.73M | $-4.28M | $-3.63M | $-3.06M | $-3.74M | $-3.86M |
| High Forecast | $-10.19M | $-9.23M | $-9.07M | $-8.92M | $-9.15M | $-10.67M | $-11.34M | $-3.62M | $-2.87M | $-9.66M | $-11.14M | $-10.19M | $-10.83M | $-10.19M | $-8.00M | $-3.86M | $-4.13M | $-3.84M | $-3.45M | $-3.84M | $-1.82M | $-6.52M | $-1.78M | $-2.07M | $-21.11M | $-3.42M | $-2.90M | $-2.45M | $-2.99M | $-3.09M |
| Low Forecast | $-10.19M | $-9.23M | $-9.07M | $-8.92M | $-9.15M | $-12.39M | $-11.34M | $-3.62M | $-2.87M | $-9.66M | $-11.14M | $-10.19M | $-10.83M | $-10.19M | $-8.00M | $-5.79M | $-6.19M | $-8.34M | $-7.51M | $-5.76M | $-2.73M | $-14.18M | $-2.67M | $-3.10M | $-45.87M | $-5.13M | $-4.35M | $-3.67M | $-4.49M | $-4.63M |
| Surprise % | - | - | - | - | - | - | - | - | 0.27% | 0.66% | 0.66% | -40.11% | 0.72% | 0.61% | - | 0.81% | 0.92% | 0.68% | 0.71% | 0.73% | 0.92% | 0.14% | 0.72% | 0.79% | 0.07% | 0.97% | 1.14% | 1.20% | 0.73% | 0.90% |
Capricor Therapeutics's average Quarter net income forecast for Jun 23 is $-11.14M, with a range of $-11.14M to $-11.14M. CAPR's average Quarter net income forecast represents a -102.73% decrease compared to the company's last Quarter net income of $408.67M (Mar 23).
Capricor Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 1 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 11 | 19 | 20 | 18 |
| SG&A | - | - | - | - | - | - | - | - | $3.21M | $3.02M | $2.85M | $3.51M | $2.79M | $2.56M | - | $1.80M | $1.79M | $1.49M | $1.30M | $1.61M | $1.14M | $876.72K | $911.97K | $831.93K | $976.49K | $1.26M | $1.18M | $1.39M | $1.09M | $1.25M |
| Avg Forecast | $57.11M | $57.11M | $45.69M | $39.98M | $89.70M | $51.15M | $52.32M | $110.80M | $121.08M | $35.98M | $34.27M | $11.42M | $114.23K | $4.80M | $4.45M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $2.40M | $799.59K | $2.51M | $2.51M | $4.91M | $2.59M | $4.08M | $3.92M | $5.61M | $12.85M |
| High Forecast | $57.11M | $57.11M | $45.69M | $39.98M | $89.70M | $59.33M | $52.32M | $110.80M | $121.08M | $35.98M | $34.27M | $11.42M | $114.23K | $4.80M | $4.45M | $3.06M | $3.06M | $3.06M | $3.06M | $3.06M | $3.06M | $1.02M | $3.21M | $3.21M | $6.27M | $3.11M | $4.90M | $4.70M | $6.73M | $15.42M |
| Low Forecast | $57.11M | $57.11M | $45.69M | $39.98M | $89.70M | $42.84M | $52.32M | $110.80M | $121.08M | $35.98M | $34.27M | $11.42M | $114.23K | $4.80M | $4.45M | $1.71M | $1.71M | $1.71M | $1.71M | $1.71M | $1.71M | $569.42K | $1.79M | $1.79M | $3.50M | $2.08M | $3.26M | $3.13M | $4.49M | $10.28M |
| Surprise % | - | - | - | - | - | - | - | - | 0.03% | 0.08% | 0.08% | 0.31% | 24.46% | 0.53% | - | 0.75% | 0.75% | 0.62% | 0.54% | 0.67% | 0.47% | 1.10% | 0.36% | 0.33% | 0.20% | 0.49% | 0.29% | 0.35% | 0.19% | 0.10% |
Capricor Therapeutics's average Quarter SG&A projection for Mar 24 is $110.80M, based on 1 Wall Street analysts, with a range of $110.80M to $110.80M. The forecast indicates a 3350.70% rise compared to CAPR last annual SG&A of $3.21M (Dec 23).
Capricor Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Sep 21 | Jun 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 | Sep 17 | Jun 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | 1 | 1 | 10 | 9 | 8 | 7 | 6 | 5 | 5 | 5 | 13 | 11 | 19 | 20 | 18 |
| EPS | - | - | - | - | - | - | - | - | $-0.02 | $-0.25 | $-0.29 | $16.19 | $-0.31 | $-0.26 | - | $-0.17 | $-0.21 | $-0.21 | $-0.20 | $-0.23 | $-0.30 | $-0.34 | $-0.43 | $-0.59 | $-0.80 | $-1.40 | $-1.40 | $-1.40 | $-1.20 | $-1.60 |
| Avg Forecast | $-0.32 | $-0.29 | $-0.28 | $-0.28 | $-0.29 | $-0.37 | $-0.36 | $-0.11 | $-0.09 | $-0.30 | $-0.35 | $-0.32 | $-0.34 | $-0.32 | $-0.26 | $-0.23 | $-0.23 | $-0.20 | $-0.18 | $-0.34 | $-0.36 | $-0.34 | $-0.68 | $-0.80 | $-1.10 | $-1.50 | $-1.10 | $-1.00 | $-2.60 | $-2.00 |
| High Forecast | $-0.32 | $-0.29 | $-0.28 | $-0.28 | $-0.29 | $-0.34 | $-0.36 | $-0.11 | $-0.09 | $-0.30 | $-0.35 | $-0.32 | $-0.34 | $-0.32 | $-0.26 | $-0.14 | $-0.14 | $-0.13 | $-0.11 | $-0.21 | $-0.23 | $-0.21 | $-0.43 | $-0.50 | $-0.69 | $-1.20 | $-0.88 | $-0.80 | $-2.08 | $-1.60 |
| Low Forecast | $-0.32 | $-0.29 | $-0.28 | $-0.28 | $-0.29 | $-0.39 | $-0.36 | $-0.11 | $-0.09 | $-0.30 | $-0.35 | $-0.32 | $-0.34 | $-0.32 | $-0.26 | $-0.31 | $-0.31 | $-0.27 | $-0.24 | $-0.46 | $-0.49 | $-0.46 | $-0.92 | $-1.09 | $-1.50 | $-1.80 | $-1.32 | $-1.20 | $-3.12 | $-2.40 |
| Surprise % | - | - | - | - | - | - | - | - | 0.28% | 0.82% | 0.83% | -50.59% | 0.91% | 0.81% | - | 0.74% | 0.91% | 1.05% | 1.11% | 0.68% | 0.83% | 1.00% | 0.63% | 0.74% | 0.73% | 0.93% | 1.27% | 1.40% | 0.46% | 0.80% |
According to 1 Wall Street analysts, Capricor Therapeutics's projected average Quarter EPS for Jun 23 is $-0.35, with a low estimate of $-0.35 and a high estimate of $-0.35. This represents a -102.16% decrease compared to CAPR previous annual EPS of $16.19 (Mar 23).
Capricor Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $3.26 | $12.00K | 367998.16% | - |
| ONTX | Traws Pharma | $1.00 | $7.00 | 600.00% | Buy |
| CAPR | Capricor Therapeutics | $4.59 | $14.00 | 205.01% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| MGTX | MeiraGTx | $4.25 | $9.00 | 111.76% | Buy |
| CDTX | Cidara Therapeutics | $11.94 | $24.00 | 101.01% | Buy |
| KROS | Keros Therapeutics | $56.98 | $105.00 | 84.28% | Buy |
| SLNO | Soleno Therapeutics | $52.84 | $72.25 | 36.73% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| ANAB | AnaptysBio | $40.33 | $36.33 | -9.92% | Buy |
CAPR Forecast FAQ
Is Capricor Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Capricor Therapeutics (CAPR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of CAPR's total ratings.
What is CAPR's price target?
Capricor Therapeutics (CAPR) average price target is $14 with a range of $14 to $14, implying a 205.01% from its last price of $4.59. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Capricor Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CAPR stock, the company can go up by 205.01% (from the last price of $4.59 to the average price target of $14), up by 205.01% based on the highest stock price target, and up by 205.01% based on the lowest stock price target.
Can Capricor Therapeutics stock reach $7?
CAPR's average twelve months analyst stock price target of $14 supports the claim that Capricor Therapeutics can reach $7 in the near future.
What are Capricor Therapeutics's analysts' financial forecasts?
Capricor Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $26.61M (high $27.33M, low $25.88M), average EBITDA is $-26.152M (high $-25.437M, low $-26.856M), average net income is $-35.808M (high $-34.776M, low $-36.497M), average SG&A $303.96M (high $312.15M, low $295.65M), and average EPS is $-1.125 (high $-1.092, low $-1.146). CAPR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $17.5M (high $17.5M, low $17.5M), average EBITDA is $-17.198M (high $-17.198M, low $-17.198M), average net income is $-37.414M (high $-37.414M, low $-37.414M), average SG&A $199.9M (high $199.9M, low $199.9M), and average EPS is $-1.175 (high $-1.175, low $-1.175).
Did the CAPR's actual financial results beat the analysts' financial forecasts?
Based on Capricor Therapeutics's last annual report (Dec 2023), the company's revenue was $25.18M, beating the average analysts forecast of $17.75M by 41.85%. Apple's EBITDA was $-23.86M, beating the average prediction of $-17.444M by 36.78%. The company's net income was $-22.288M, missing the average estimation of $-33.859M by -34.17%. Apple's SG&A was $12.59M, missing the average forecast of $202.75M by -93.79%. Lastly, the company's EPS was $-0.83, missing the average prediction of $-1.063 by -21.94%. In terms of the last quarterly report (Dec 2023), Capricor Therapeutics's revenue was $12.09M, beating the average analysts' forecast of $10.6M by 14.04%. The company's EBITDA was $-1.063M, missing the average prediction of $-10.417M by -89.80%. Capricor Therapeutics's net income was $-762K, missing the average estimation of $-2.866M by -73.41%. The company's SG&A was $3.21M, missing the average forecast of $121.08M by -97.35%. Lastly, the company's EPS was $-0.0249, missing the average prediction of $-0.09 by -72.33%